Exheus Closes €900,000 Round Led by Decelera Ventures

Exheus increases capital to continue growing. The Spanish company specializing in RNA analysis has closed a financing round of €900,000, an amount that will help it to start its international expansion. The round was led by Decelera Ventures I FCR.

WA4Steam, NextGen Venture Partners, as well as other investors through the Capital Cell platform, have also participated in the round, investing €650,000. This investment is complemented by another 250,000 euros received from a line of financing provided by the Center for Technological and Industrial Development (Cdti), an entity that depends on the Ministry of Science and Innovation.

In addition to this funding, which totals €900,000, Exheus has also received a grant of €50,000 from EIT Health, a European organization that promotes innovation in health.

Read more about Exheus and discover the world’s most interesting financial news with the mobile app Born2Invest. The app provides its readers access to the latest news in global business, stock market, finance news, and also trending topics like bitcoin, cryptocurrency, and biotech.

Exheus has also received a grant of €50,000 from EIT Health

Exheus will use the resources obtained to initiate international expansion in Europe, create a commercial structure that will enable it to access the healthcare system in European countries, and work on the regularization of the legal requirements necessary for the company to operate on an international scale.

Exheus also plans to digitize the product following a B2B approach so that, with the development of a digital, automated and interactive platform, healthcare professionals can directly access the patient’s results and, with this, give an assessment of their RNA test.

Exheus was born in 2020 as a spin-off of the Genomics of Complex Diseases Research Group of the Hospital Sant Pau-IIB Sant Pau Research Institute, the Center for Research in Biomedical Engineering (Creb) of the Universitat Politècnica de Catalunya-BarcelonaTech (UPC), Summit and Mobile World Capital Barcelona’s innovation program, The Collider.

The company analyzes the expression of all the genes in the human body

The company analyzes the expression of all the genes in the human body present in the blood transcriptome to detect and correct anomalies that affect a person’s health. Thanks to this analysis, the expression levels of all the genes in the genome are monitored, making it possible for healthcare professionals to offer personalized recommendations and optimize the intervention for their patients.

Exheus tests are based on blood analysis. The tests are able to sequence mRNA, detect biomarkers and define in a more individualized way the functioning of the user’s organism.

Since its foundation, the Spanish company has raised more than €500,000 in funding and has participated in numerous acceleration programs such as Google For Startups, Decelera, or Kunsen VC.

__

(Featured image by qimono via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.